Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
losartan
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Losartan is an angiotensin II receptor blocker (ARB) used primarily to treat high blood pressure (hypertension), reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, and manage kidney disease in people with type 2 diabetes and a history of hypertension. It works by selectively blocking the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone secretion, which leads to relaxation of blood vessels, reduced blood pressure, decreased workload on the heart, and renal protection. Losartan is available as an oral tablet or suspension.
- Brand names
- CozaarArbli
- Other names
- losartan potassiumlosartanumlorastanallisartanLortaan
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)ACE (Angiotensin Converting Enzyme)DRD1 (Dopamine D1 Receptor)
Beyond the preview
Go deeper on losartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on losartan.